@article{940724c35a7e45dd821fa4e6faf30705,
title = "Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large b cell lymphoma and grade iii follicular lymphoma",
abstract = "Patients with chemorefractory non-Hodgkin lymphomas generally have a poor prognosis. We used the observational database of the Center for International Blood and Marrow Transplant Research to study the outcome of 533 patients with refractory diffuse large B cell lymphoma (DLBCL) or grade III follicular lymphoma (FL-III) who underwent allogeneic hematopoietic cell transplantation (allo-HCT) using either myeloablative (MA; n = 307) or reduced-intensity/nonmyeloablative conditioning (RIC/NST; n = 226) between 1998 and 2010. We analyzed nonrelapse mortality (NRM), relapse/progression, progression-free survival (PFS), and overall survival (OS). Only 45% of the patients at transplantation had a Karnofsky performance score of ≥90%. Median follow-up of surviving patients after MA and RIC/NST allo-HCT is 35 months and 30 months, respectively. At 3 years, MA allo-HCT was associated with a higher NRM compared with RIC/NST (53% versus 42%; P = .03), similar PFS (19% versus 23%; P = .40), and lower OS (19% versus 28%; P = .02), respectively. On multivariate analysis, FL-III histology was associated with lower NRM (relative risk [RR], .52), reduced risk of relapse/progression (RR, .42), and superior PFS (RR, .51) and OS (RR, .53), whereas MA conditioning was associated with reduced risk of relapse/progression (RR, .66). Despite a refractory state, a small subset of DLBCL and FL-III patients can attain durable remissions after allo-HCT. Conditioning regimen intensity was not associated with PFS and OS despite a higher risk of relapse/progression with RIC/NST allo-HCT.",
author = "Mehdi Hamadani and Wael Saber and Ahn, {Kwang Woo} and Jeanette Carreras and Cairo, {Mitchell S.} and Fenske, {Timothy S.} and Gale, {Robert Peter} and John Gibson and Hale, {Gregory A.} and Hari, {Parameswaran N.} and Hsu, {Jack W.} and Inwards, {David J.} and Kamble, {Rammurti T.} and Anderas Klein and Dipnarine Maharaj and Marks, {David I.} and Rizzieri, {David A.} and Savani, {Bipin N.} and Schouten, {Harry C.} and Waller, {Edmund K.} and Baldeep Wirk and Laport, {Ginna G.} and Silvia Montoto and Maloney, {David G.} and Lazarus, {Hillard M.}",
note = "Funding Information: Financial disclosure : The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA76518 from the National Cancer Institute, the National Heart, Lung and Blood Institute, and the National Institute of Allergy and Infectious Diseases ; a Grant/Cooperative Agreement 5U01HL069294 from the National Heart, Lung and Blood Institute and the National Cancer Institute ; a contract HHSH234200637015C with Health Resources and Services Administration; two grants N00014-06-1-0704 and N00014-08-1-0058 from the Office of Naval Research ; and grants from Allos, Inc., Amgen, Inc., Angioblast, anonymous donation to the Medical College of Wisconsin, Ariad, Be the Match Foundation, Blue Cross and Blue Shield Association, Buchanan Family Foundation, CaridianBCT, Celgene Corporation, CellGenix, GmbH, Children's Leukemia Research Association, Fresenius-Biotech North America, Inc., Gamida Cell Teva Joint Venture Ltd., Genentech, Inc., Genzyme Corporation, GlaxoSmithKline, HistoGenetics, Inc., Kiadis Pharma, The Leukemia & Lymphoma Society, The Medical College of Wisconsin, Merck & Co, Inc., Millennium: The Takeda Oncology Co., Milliman USA, Inc., Miltenyi Biotec, Inc., National Marrow Donor Program, Optum Healthcare Solutions, Inc., Osiris Therapeutics, Inc., Otsuka America Pharmaceutical, Inc., RemedyMD, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals, Soligenix, Inc., StemCyte, A Global Cord Blood Therapeutics Co., Stemsoft Software, Inc., Swedish Orphan Biovitrum, Tarix Pharmaceuticals, Teva Neuroscience, Inc., THERAKOS, Inc., and Wellpoint, Inc. ",
year = "2013",
month = may,
doi = "10.1016/j.bbmt.2013.01.024",
language = "English (US)",
volume = "19",
pages = "746--753",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "5",
}